Ämnen: Haelso-sjukvaard

New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population

5 Oktober 2012 13:27

Paris, France – October 5, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results from the landmark ORIGIN trial showing treatment with Lantus® was approximately 3-fold more likely to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular risk.

Sanofi Diabetes supports “Start Right, Eat Right” nutritional initiative

3 Oktober 2012 14:04

Sanofi Diabetes is funding “Start Right, Eat Right”, a public nutrition initiative taking place in Berlin, Germany, October 2nd - October 5th 2012. This event coincides with the 48th Annual Meeting of the European Association of the Study of Diabetes (EASD).

Sanofi to Acquire Genfar S.A., a Leader in Pharmaceutical Medicines in Colombia

3 Oktober 2012 10:06

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has signed an agreement to acquire Genfar S.A., a leading pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will become a market leader in Colombia and expand its portfolio of affordable pharmaceuticals in Latin America.

Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement

3 Oktober 2012 10:01

Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint

2 Oktober 2012 15:49

Paris, France - October 2, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in previously untreated patients with Gaucher disease type 1, met its primary endpoint.

Lyxumia® (lixisenatide)* in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Improved Glycemic Control

2 Oktober 2012 13:52

Sanofi (EURONEXT: SAN and NYSE: SNY) today announced results from a study showing that the mechanism of action of once-daily Lyxumia® (lixisenatide) significantly delayed gastric emptying, a process accompanied by significant post-prandial glucose (PPG) lowering.

Sanofi and TB Alliance Announce Collaboration to Accelerate New Treatments Against Tuberculosis

20 September 2012 10:33

Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB Drug Development (TB Alliance) announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide1 in 2010.

FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis

12 September 2012 09:00

Paris, France – September 12, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

Anna-Kaija Grönblad ny vd för Sanofi Sverige

3 September 2012 08:28

Stockholm – 3 september 2012 – Sanofi meddelar idag att Anna-Kaija Grönblad efterträder Laurent Dousset som vd för Sanofi Sverige. Hon kommer samtidigt att bli divisionschef för onkologi i Norden och Baltikum. Laurent Dousset går vidare till en ny position på huvudkontoret i Paris.

Genzyme Provides Update on U.S. LEMTRADA™(*) Filing

27 Augusti 2012 16:19

Paris, France - August 27, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced that Genzyme has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of LEMTRADA™ (alemtuzumab) as a treatment for relapsing multiple sclerosis.

U.S. FDA Approves ZALTRAP® (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer

6 Augusti 2012 13:06

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.

Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes

20 Juni 2012 10:37

Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, today announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.

Sanofi Voted Leading Pan-European Quoted Company for Investor Relations in the 2012 Thomson Reuters Extel Survey

15 Juni 2012 13:52

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it was granted the award for “Leading Pan-European Quoted Company for Investor Relations” in the 2012 Thomson Reuters Extel Survey. Considered the leading benchmark for excellence in Investor Relations (IR), the survey highlights achievement across companies listed in Europe.

Sanofi presenterar resultat från världens största och längsta randomiserade studie inkluderande personer med tidig typ 2-diabetes och förstadier till typ 2-diabetes

12 Juni 2012 15:20

Den internationella studien ORIGIN (Outcome Reduction with Initial Glargine Intervention) har undersökt om det går att förhindra eller skjuta upp kardiovaskulära händelser som kan följa av typ 2-diabetes och om man kan förhindra utvecklingen av typ 2-diabetes hos personer som riskera få denna sjukdom, genom att behandla med Lantus® (insulin glargin) på ett tidigare stadium än vad som görs idag.

Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ (alemtuzumab) for Multiple Sclerosis

12 Juni 2012 13:40

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA™ (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).

New Epidemiological Data Provide Additional Safety Evidence for Lantus® – No increased risk of cancer found with Lantus® in new European and U.S. observational studies

12 Juni 2012 10:52

Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States.

Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes

11 Juni 2012 13:16

Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus® (insulin glargine [rDNA origin] injection) versus sitagliptin. These data from the EASIE study were presented at the American Diabetes Association 72nd Scientific Sessions.

Läkemedel från ödlesaliv sänker blodsockret - Fas 3-studier på patienter med typ 2-diabetes visar att behandling med lixisenatid signifikant minskar långtidsblodsockret (HbA1c).

11 Juni 2012 09:12

Sanofi presenterar studieresultat från prövningsprogrammet GetGoal som visar att lixisenatid, som tillägg till basinsulin och perorala diabetesläkemedel, signifikant sänker långtidsblodsockret (HbA1c) både hos de patienter med typ 2-diabetes som nyligen har påbörjat sin behandling med insulin, och hos de patienter som har behandlats med insulin en längre tid (i genomsnitt 3,1 år).

Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis

1 Juni 2012 13:10

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today top-line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once-daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis (MS).

Sanofi Inaugurates Lantus® SoloSTAR® Pen Assembly Plant in its Beijing Facility - The Group Pledges Continuous Commitment to Diabetes Management in China

29 Maj 2012 17:04

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the inauguration of a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus® SoloSTAR® at its Beijing plant located at the Beijing Economic-Technological Development Area (BDA).